Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.41 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.41 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.41 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4229381 | 0.91 | PLAAT3 (0.45) | CAPN1LMNAPLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4211214 | 0.88 | KMT2A (0.44) | CAPN1LMNAPLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4218382 | 0.88 | KMT2A (0.44) | CAPN1LMNAPLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4211218 | 0.88 | KMT2A (0.44) | CAPN1LMNAPLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4221631 | 0.83 | NPC1 (0.39) | SMN1; SMN2ALDH1A1ATM | |
| SCHEMBL4213902 | 0.82 | PTGS2 (0.39) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL4612173 | 0.82 | PTGS2 (0.39) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL4216131 | 0.82 | PTGS2 (0.39) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL4215534 | 0.82 | PTGS2 (0.40) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL4214810 | 0.82 | PLAAT3 (0.45) | LMNAPLAAT3PLAAT5PLAAT2PLAAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383652-B2 | Biaromatic compounds that modulate PPAR-receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-02-26 | — | — | US | disclosed |
| US-20090012129-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-08 | — | — | US | disclosed |
| EP-1943213-A2 | PPAR MODULATING BIAROMATIC COMPOUNDS | Galderma Research & Development (FR) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007049158-A2 | PPAR MODULATING BIAROMATIC COMPOUNDS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012129-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS | PPARG, PPARD, PPARA | CAPN1 3475/4885LMNA 3394/4885PLAAT3 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.